News und Analysen
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement